Caplin Point Board Approves Q1 FY27 Results, Recommends Final Dividend, Appoints Directors
Caplin Point Laboratories approved Q1 FY27 results showing consolidated revenue of ₹643.91 Crores and PAT of ₹179.09 Crores. The Board recommended a final dividend of ₹4 per share. Dr. Sridhar Ganesan was re-appointed as MD, and Mr. D. Muralidharan as Whole-Time Director. The AGM is on September 25, 2026.
The announcement includes financial results, dividend recommendation, and significant management appointments, all of which are material information for investors.
The company reported positive financial results with increased revenue and profit, recommended a final dividend, and re-appointed key management personnel, all indicating a stable and growing business.
Caplin Point Laboratories Limited announced the outcome of its Board Meeting held on August 12, 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the Limited Review Report and an investor presentation.
The company recommended a Final Dividend of ₹4/- (200%) per equity share for the financial year ended March 31, 2026, subject to shareholder approval at the upcoming Annual General Meeting (AGM). The record date for this dividend will be communicated separately.
In terms of leadership, the Board approved the re-appointment of Dr. Sridhar Ganesan as the Managing Director for a further period of two years, effective August 25, 2026, subject to shareholder approval. Additionally, Mr. D. Muralidharan was appointed as the Whole-Time Director for two years from August 12, 2026, and will continue as Chief Financial Officer.
The 35th Annual General Meeting (AGM) of the Company is scheduled to be held on Friday, September 25, 2026, through Video Conferencing. The meeting commenced at 10:45 AM and concluded at 1:25 PM.
What to do with a filing like this
Caplin Point Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Caplin Point Laboratories Limited. Read the original for the full detail.